close
Add to watchlist
NPS Pharmaceuticals Inc (NPSP) Healthcare, Biotechnology & Drugs
NPS Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development of specialty therapeutics for gastrointestinal and endocrine disorders. The company is advancing two late-stage programs to restore or replace biological function, including GATTEX (teduglutide), which is in Phase 3 clinical development for parenteral dependent short bowel syndrome; and NPSP558 (parathyroid hormone 1-84 [rDNA origin] injection) that is in Phase 3 clinical development as a hormone therapy for hypoparathyroidism. It complements its internal programs with strategic partnerships with Amgen, GlaxoSmithKline, Kyowa Kirin, and Nycomed. The company was founded in 1986 and is headquartered in Bedminster, New Jersey.
(login to add this stock to your watchlist or favorites)
Key Statistics
| Closing Price | 6.86 |
| Volume | 501079 |
| Volume Avg | 771881 |
| 52 Week High | 10.75 |
| 52 Week Low | 4.35 |
| PE | N/A |
| PE (group average) | 39 |
| EPS Year | -0.45 |
| EPS change Q/Q | -65.38% |
| EPS change Q/Q Yr ago | -125% |
| EPS change Q/Q next Q est | 0% |
| EPS change Y/Y | -28.85% |
| REV change Q/Q | 13.74% |
| REV change Q/Q Yr ago | 9.09% |
| EPS next Q est | -0.09 |
| EPS next Y est | 0.37 |
| Divident Annual | 0.00 |
| Dividend Yield | 0% |